Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Cipher Pharmaceuticals (TSE:CPH)
TSX:CPH
Holding TSE:CPH?
Track your performance easily
Earnings Data
Report Date
Mar 13, 2025TBA Not Confirmed
Period Ending
2024 (Q4)Consensus EPS Forecast
0.28Last Year’s EPS
0.43Same Quarter Last Year
Moderate Buy
Based on 1 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:Nov 07, 2018
|% Change Since: -9.85%
|Next Earnings Date:Aug 10, 2018
Earnings Call Sentiment|Neutral
The earnings call presented a mixed view of Cipher Pharmaceuticals' performance. The company showcased significant revenue growth and gross margin improvements driven by the Natroba acquisition and Epuris sales. However, challenges such as the decline in Absorica licensing revenue, transition impacts on sales, and setbacks in the Moberg Phase III study indicate areas of concern. The company remains optimistic about future growth opportunities and strategic expansions.Company Guidance
During Cipher Pharmaceuticals' Q3 2024 earnings call, several key metrics and strategic insights were shared. The company reported total net revenue of $10.4 million for the quarter, marking a 71% increase compared to the same period last year, primarily driven by the acquisition of the Natroba business. Product revenue increased by 213% to $9.3 million, with Natroba contributing $5.5 million. Gross margin improved to 79%, up from 64% in Q3 2023, bolstered by the high-margin Natroba products. Despite a decrease in licensing revenue, mainly from Absorica, the company remains optimistic about its strategy to grow Natroba sales organically and through out-licensing globally. Adjusted EBITDA for the quarter was $4.1 million, and the company ended with $9.5 million in cash, positioning it well for future acquisitions. The transition from a co-promotion partner for Natroba is expected to complete by end 2024, with anticipated benefits in 2025. Additionally, Cipher is exploring M&A opportunities, looking at assets generating over $30 million annually, aiming to expand its dermatology and infectious disease portfolio.Natroba Acquisition and Integration
Cipher Pharmaceuticals completed the acquisition of Natroba and its authorized generic, spinosad, from ParaPRO. The integration into Cipher's infrastructure is progressing well, providing a North American platform for growth.
Revenue Increase
Total net revenue for Q3 2024 increased by $4.3 million or 71% compared to the same quarter in the prior year, driven by the Natroba acquisition.
Epuris Sales Growth
Product revenue from Epuris increased by $0.9 million or 32% for the third quarter of 2024 compared to the same period in 2023, with market share rising to 50.3%.
Increased Gross Margin
Gross margin on product revenue increased by 15% to 79% for the third quarter of 2024, due to the addition of Natroba and spinosad products.
Strategic Expansion Plans
Cipher plans to out-license Natroba globally and bring it to Canada, leveraging their direct sales platform and dermatology product portfolio.
Pipeline Developments
Positive developments in the pipeline include plans to expand the partnership with Can-Fite for piclidenoson in other indications and territories.
---
TSE:CPH Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
TSE:CPH Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
| Nov 07, 2024 | C$15.54 | C$13.88 | -10.68% |
| Aug 08, 2024 | C$13.81 | C$14.43 | +4.49% |
| May 09, 2024 | C$8.95 | C$9.25 | +3.35% |
| Mar 14, 2024 | C$7.13 | C$8.10 | +13.60% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does Cipher Pharmaceuticals (TSE:CPH) report earnings?
Cipher Pharmaceuticals (TSE:CPH) is schdueled to report earning on Mar 13, 2025, TBA Not Confirmed.
What is Cipher Pharmaceuticals (TSE:CPH) earnings time?
Cipher Pharmaceuticals (TSE:CPH) earnings time is at Mar 13, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is TSE:CPH EPS forecast?
TSE:CPH EPS forecast for the fiscal quarter 2024 (Q4) is 0.28.
---